COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,441 Articles (22,835 medRxiv, 8,606 bioRxiv)

Most recent first Previous |  Page 2386: Articles 23851-23860  | Next

Suppression of MDA5-mediated antiviral immune responses by NSP8 of SARS-CoV-2
Yang, Z., Zhang, X., Wang, F., Wang, P., Li, X., Kuang, E.
10.1101/2020.08.12.247767 — Posted: 2020-08-12
TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2
Wang, Y., Fan, Y., Huang, Y., Du, T., Liu, Z., Huang, D., Wang, Y., Wang, N., Zhang, P.
10.1101/2020.08.12.247825 — Posted: 2020-08-12
Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection
Wang, C., Wang, S., Chen, Y., Zhao, J., Han, S., Zhao, G., Kang, J., Liu, Y., Wang, L., Wang, X., Xu, Y., Wang, S., Huang, Y., Wang, J., Zhao, J.
10.1101/2020.08.12.247338 — Posted: 2020-08-12
Efficacy of Targeting SARS-CoV-2 by CAR-NK Cells
Ma, M. T., Badeti, S., Geng, K., Liu, D.
10.1101/2020.08.11.247320 — Posted: 2020-08-12 Discussion: Onsite
Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2
Walls, A. C., Fiala, B., Schaefer, A., Wrenn, S., Pham, M. N., Murphy, M., Tse, L. V., Shehata, L., O'Connor, M. A., Chen, C., Navarro, M. J., Miranda, M. C., Pettie, D., Ravichandran, R., Kraft, J. C., Ogohara, C., Palser, A., Chalk, S., Lee, E.-C., Kepl, E., Chow, C. M., Sydeman, C., Hodge, E. A., Brown, B., Fuller, J. T., Dinnon, K., Gralinski, L., Leist, S. R., Gully, K. L., Lewis, T. B., Guttman, M., Chu, H. Y., Lee, K. K., Fuller, D. H., Baric, R. S., Kellam, P., Carter, L., Pepper, M., Sheahan, T. P., Veesler, D., King, N. P.
10.1101/2020.08.11.247395 — Posted: 2020-08-12 Discussion: Onsite
The effect of public health policies in the transmission of COVID-19 for South American countries
Valcarcel, B., Avilez, J. L., Torres-Roman, J. S., Poterico, J. A., Bazalar-Palacios, J., La Vecchia, C.
10.1101/2020.08.09.20149286 — Posted: 2020-08-12
Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase
White, M. A., Lin, W., Cheng, X.
10.1101/2020.08.09.243246 — Posted: 2020-08-12 Discussion: Onsite
Worldwide tracing of mutations and the evolutionary dynamics of SARS-CoV-2
Zhou, Z.-Y., Liu, H., Zhang, Y.-D., Wu, Y.-Q., Peng, M.-S., Li, A., Irwin, D. M., Li, H., Lu, J., Bao, Y., Lu, X., Liu, D., Zhang, Y.-P.
10.1101/2020.08.07.242263 — Posted: 2020-08-12
Love during lockdown: findings from an online survey examining the impact of COVID-19 on the sexual practices of people living in Australia
Coombe, J., Kong, F., Bittleston, H., Williams, H., Tomnay, J., Vaisey, A., Malta, S., Goller, J., Temple-Smith, M., Bourchier, L., Lau, A., Chow, E., Hocking, J. S.
10.1101/2020.08.10.20171348 — Posted: 2020-08-12
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings
buonsenso, d., Valentini, P., De Rose, C., Pata, D., Sinatti, D., Speziale, D., Ricci, R., Carfi, A., Landi, F., Sanguinetti, M., Sali, M.
10.1101/2020.08.10.20169912 — Posted: 2020-08-12

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).